Current standard vaccine testing protocols take approximately 10-24 months of testing before a vaccine can be declared successful. Sometimes by the time a successful vaccine is out for public use, the outbreak may already be over. With no vaccine or antiviral drug available to treat the infected, we are left with the age-old methods of isolation, quarantine, and rest, to arrest such a viral outbreak. Convalescent blood therapy and covalent plasma therapy have often proved effective in reducing mortality, however, the role of innate and adaptive immune cells in these therapies have been overlooked. Antigen presenting cells (APCs), CD4+ T memory cells, CD8+ T memory cells, and memory B-Cells all play a vital role in sustainable defense and subsequent recovery. This report incorporates all these aspects by suggesting a novel treatment therapy called selective convalescent leukapheresis and transfusion (SCLT) and also highlights its potential in vaccination. The anticipated advantages of the proposed technique outweigh the cost, time, and efficiency of other available transfusion and vaccination processes. It is envisioned that in the future this new approach could serve as a rapid emergency response to subdue a pathogen outbreak and to stop it from becoming an epidemic, or pandemic.

中文翻译：

---

假设：通过选择性恢复期血液工程进行免疫疗法来抑制 COVID-19 等疾病。


目前的标准疫苗测试方案大约需要 10-24 个月的测试时间才能宣布疫苗成功。有时，当成功的疫苗可供公众使用时，疫情可能已经结束。由于没有疫苗或抗病毒药物来治疗感染者，我们只能采用古老的隔离、隔离和休息方法来阻止病毒的爆发。恢复期血液疗法和共价血浆疗法通常被证明可以有效降低死亡率，然而，先天性和适应性免疫细胞在这些疗法中的作用却被忽视了。抗原呈递细胞 (APC)、CD4+ T 记忆细胞、CD8+ T 记忆细胞和记忆 B 细胞在可持续防御和随后的恢复中都发挥着至关重要的作用。该报告综合了所有这些方面，提出了一种称为选择性恢复期白细胞去除和输血（SCLT）的新型治疗方法，并强调了其在疫苗接种方面的潜力。所提出技术的预期优势超过了其他可用输血和疫苗接种过程的成本、时间和效率。预计未来这种新方法可以作为快速应急响应来抑制病原体爆发并阻止其成为流行病或大流行病。